|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:activities
|
serotonin reuptake inhibitor
|
|
gptkbp:clinical_trial
|
gptkb:United_States
high
Phase 2
promising
|
|
gptkbp:collaborations
|
University of Medicine
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:developed_by
|
gptkb:Alchem_Laboratories
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:duration
|
8 weeks
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:field_of_study
|
pharmacology
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0733
|
|
gptkbp:indication
|
gptkb:historical_event
anxiety disorders
bipolar disorder
|
|
gptkbp:ingredients
|
C20 H24 N2 O2
|
|
gptkbp:interacts_with
|
MAO inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of neurological disorders
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not yet marketed
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
adults
|
|
gptkbp:publishes
|
gptkb:Journal_of_Affective_Disorders
gptkb:American_Journal_of_Psychiatry
gptkb:Journal_of_Pharmacology
gptkb:Journal_of_Clinical_Psychiatry
gptkb:Frontiers_in_Pharmacology
gptkb:Clinical_Trials_Journal
gptkb:Archives_of_General_Psychiatry
gptkb:European_Journal_of_Pharmacology
gptkb:Neuroscience_Letters
Psychopharmacology
|
|
gptkbp:receives_funding_from
|
gptkb:Research_Institute
|
|
gptkbp:safety_features
|
well-tolerated
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
insomnia
dry mouth
weight gain
|
|
gptkbp:status
|
ongoing
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
serotonin receptors
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
324.42 g/mol
|
|
gptkbp:year_created
|
gptkb:2020
|